Biotech

All Articles

Analysts go into Avidity's DMD succeed, uncovering subtleties in information

.Avidity Biosciences impressed financiers along with period 1/2 information in Duchenne muscular dys...

Actinogen's cortisol blocker falls short phase 2 clinical depression research study

.Actinogen Medical's cortisol blocker has missed out on the key endpoint of a stage 2 research in de...

Bivictrix chooses going private only method to take ADC into clinic

.Antibody-drug conjugates (ADCs) have been at the facility of many a billion-dollar biobuck licensin...

TPG tops up funds to $580M for assets all over life sciences

.Possession supervisor TPG, which has supported biotechs like Sionna Rehabs and Santa Clam Ana Biogr...

Merck quits period 3 TIGIT trial in bronchi cancer cells for futility

.Merck &amp Co.'s TIGIT program has suffered yet another trouble. Months after shuttering a period 3...

After a difficult year, Exscientia folds up into Recursion

.After a year determined through pipe cuts, the variation of its own chief executive officer and als...

Cullinan, after $25M bargain, return bispecific to Harbour

.Cullinan Therapy was wowed good enough with Harbour BioMed's bispecific immune system reactor that ...

A better consider Ferocious Biotech's Tough 15

.In this week's incident of "The Top Line," our team're diving into Brutal Biotech's annual Strong 1...

Lilly encounters phase 2 failing of tau-targeting med

.The confetti is actually still flying from Eli Lilly's gathering commemorating the approval of Alzh...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our roundup of significant management hirings, shootings...